Prof Shahneen Sandhu
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
525 Scholarly works
10 Projects
HIGHLIGHTS
2026
Journal article
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
DOI: 10.1186/s13059-026-04074-22026
Journal article
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience
DOI: 10.1016/j.ejca.2026.1168652026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
DOI: 10.1038/s41467-026-74334-z2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.0022017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
2017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
DOI: 10.1038/s41467-026-74076-y2026
Journal article
NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
DOI: 10.1200/jco.2026.44.16_suppl.tps96102026
Journal article
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
DOI: 10.1200/jco.2026.44.16_suppl.95692026
Journal article
A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.
DOI: 10.1200/jco.2026.44.16_suppl.tps51362026
Journal article
Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.
DOI: 10.1200/jco.2026.44.16_suppl.tps26662026
Journal article
BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).
DOI: 10.1200/jco.2026.44.16_suppl.tps51372026
Journal article
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
DOI: 10.1158/1078-0432.CCR-25-3951
RECENT PROJECTS
2021
Research grants (international)
Identifying Genetic, Transcriptional and Microenvironment Drivers of Lethal Prostate Cancer for Better Patient Stratification, Disease Tracking and Drug Target Discovery